SpectrumX Holdings UK Ltd co-founder and CEO Damien Hancox visited Proactive's London studio to talk about how SpectrumX has performed during 2022.
He gives his view of how the company has been evolving and reveals what investors can expect from the coming year.
Hancox describes 2022 as "exciting and busy" and that it is now ready to move forward with its first in-human clinical trial.